Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan, ATG, and Fludarabine Conditioning for Pediatric SCT
NCT00305708Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2000
- Primary completion
- Jul 2004
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine, antithymocyte globulin rabbit in aplastic anemia, Diamond-Blackfan anemia (DBA), severe congenital neutropenia (SCN), Amegakaryocytic Thrombocytopenia (CAMT), beta thalassemia, sponsored by University of California, San Francisco. Started Aug 2000; status: completed.
02
Drugs
busulfanfludarabineantithymocyte globulin rabbit
03
Conditions
aplastic anemiaDiamond-Blackfan anemia (DBA)severe congenital neutropenia (SCN)Amegakaryocytic Thrombocytopenia (CAMT)beta thalassemia
Beyond the preview
Go deeper on NCT00305708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305708.